Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PDGFRA
REST API REST API
Homo sapiens
PDGFRA is differentially expressed in 296 experiments: 157 organism parts: bone marrow, ovary, ... (155 more);, 254 disease states: normal, glioblastoma, ... (252 more);, 107 cell types 299 cell lines 32 compound treatments and 76 other conditions.
Synonyms CD140a, PDGFR2
Orthologs F1N870_CHICK (Gallus gallus)   Pdgfra (Mus musculus)   F1MX49_BOVIN (Bos taurus)   Pdgfra (Rattus norvegicus)   Pvr (Drosophila melanogaster)   pdgfra (Xenopus laevis)   Q6E7G6_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, gliogenesis, protein binding, cytoplasm, wound healing, positive regulation of cell proliferation, membrane, peptidyl-tyrosine phosphorylation, male genitalia development, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, female gonad development, ATP binding, anatomical structure morphogenesis, transferase activity, transferring phosphorus-containing groups, integral to plasma membrane, estrogen metabolic process, nucleus, response to hormone stimulus, positive regulation of DNA replication, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, protein homodimerization activity, integral to membrane, extracellular matrix organization, organ morphogenesis, protein kinase activity, response to cytokine stimulus, luteinization, in utero embryonic development, adrenal gland development, inner ear development, platelet-derived growth factor receptor signaling pathway, positive regulation of cell migration, platelet-derived growth factor alpha-receptor activity, response to estrogen stimulus, cardiac myofibril assembly, response to inorganic substance, positive regulation of fibroblast proliferation, response to estradiol stimulus, lung development, growth factor binding, platelet-derived growth factor binding, skeletal system morphogenesis, palate development, response to organic substance, odontogenesis of dentine-containing tooth, vascular endothelial growth factor receptor signaling pathway, response to hyperoxia, cell activation, platelet-derived growth factor receptor binding, face morphogenesis, Leydig cell differentiation, protein autophosphorylation, protein phosphorylation, retina vasculature development in camera-type eye, signal transduction involved in regulation of gene expression, platelet-derived growth factor receptor-alpha signaling pathway, cellular response to amino acid stimulus, metanephric glomerular capillary formation, phosphatidylinositol 3-kinase binding, vascular endothelial growth factor-activated receptor activity
InterPro Term Ig_sub, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Ig_I-set, Tyr_kinase_VEGFR_rcpt_N, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Tyr_kinase_CSF1/PDGF_rcpt, Se/Thr_kinase-like_dom
UniProt Accession P16234, D6RDX0, D6RIG5, D6RG11, D6RJH0, E9PBH0
Gene-Disease Assocation HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES, GASTROINTESTINAL STROMAL TUMOR; GIST
Search EB-eye ENSG00000134853
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-5823, E-GEOD-3529
HL-60
2
E-GEOD-5258, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
SW620
2
E-MEXP-1014, E-MTAB-37
WI38
2
E-MTAB-37, E-MTAB-62
GM10832
1
E-TABM-321
293 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (50 experiments)

Factor Value U/D Experiments
stromal cell
1
5
E-MEXP-2034, E-GEOD-3998, E-GEOD-1460, E-MEXP-1327, E-MEXP-1121, ... (6 experiments)
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
dendritic cell
2
E-MEXP-2019, E-GEOD-360
macrophage
2
E-GEOD-3982, E-GEOD-360
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (66 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4290
chronic myelogenous leukemia
3
E-MTAB-62, E-GEOD-5550, E-GEOD-96
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
248 more value(s).


Compound treatment

studied in E-GEOD-1432, E-GEOD-3720, E-TABM-868, E-GEOD-5099, E-GEOD-15811, ... (21 experiments)

Factor Value U/D Experiments
interferon-gamma + lipopolysaccharide
2
E-GEOD-5099, E-GEOD-7307
unknown
1
E-GEOD-7307
platelet-derived growth factor
1
E-GEOD-1923
M-CSF
1
E-GEOD-5099
lipopolysaccharide
1
E-TABM-868
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
26 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
86 years
1
1
E-GEOD-4922


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-22056, E-TABM-36, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-MEXP-2657, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-GEOD-16363, E-GEOD-430, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.368 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM